Verici Dx PLC (AIM:VRCI) shares jumped 19% higher after the developer of advanced clinical diagnostics for organ transplant announced successful validation results from its prospective, blinded, international multi-centre clinical study for Clarava.
Clarava is the first pre-transplant prognostic test to enable measurement of a patient's immune response to assess the risk of early kidney graft rejection. The validation study represents a significant demonstration of Clarava as a predictive test capable of informing a clear, actionable response from clinicians for an estimated 65,000 eligible patients on an annual basis.
Verici Dx said it is on track to commence the initial US commercial launch of Clarava before the end of 2023, with Clarava to be offered in conjunction with the company's other lead product, Tutivia, which is already available in the US.
In a statement, Sara Barrington, CEO of Verici Dx, commented: "With Tutivia commercially launched as a measure for post-transplant rejection risk, the addition of Clarava as a pre-transplant test is a significant milestone in our strategy of building a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians, to help personalise care and transform outcomes."
Around 9.15am, Verici Dx shares were up 19.2% at 14p.